Clinical trials
Liver Transplant Rejection clinical trials
Below are recruiting liver transplant rejection clinical trials, each written for real people, not researchers. We’re tracking 37 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07006532Recruiting
Tocilizumab for chronic active antibody-mediated rejection
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
TehranAges 18 years+ - NCT06918990RecruitingPhase 1
CarBel for antibody-mediated rejection after kidney transplant
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
Birmingham, AlabamaAges 18–75 - NCT06801886Enrolling by invitationPhase 3
Silymarin for better kidney transplant success
This trial tests if adding silymarin (a milk thistle extract) to standard anti-rejection medicines helps protect the new kidney from damage. It may improve how well the transplanted kidney works over time.
MartinAges Any age - NCT07549503RecruitingPhase 2
Liver Transplant Immune Changes Study
This research study tracks early signs of immune system changes in children who received a liver transplant 3–7 years ago and are doing well. By studying blood and liver samples, researchers hope to better understand how to prevent rejection and improve long-term transplant survival.
San Francisco, CaliforniaAges 3–13 - NCT06398457RecruitingEarly Phase 1
Darzalex Before Stem Cell Transplant for High-Risk Graft Failure
This trial tests giving a drug called Darzalex Faspro before the usual desensitization and a stem cell transplant for people at high risk of graft failure due to donor-specific antibodies. The goal is to prevent the transplant from failing.
Baltimore, MarylandAges 18 years+ - NCT07335523Recruiting
Testing for poor digestion in Alagille syndrome after liver transplant
This study looks for signs of poor digestion after a liver transplant in people with Alagille syndrome. You collect stool samples for 3 days while on a high-fat diet to see if your pancreas is making enough enzymes.
Aurora, ColoradoAges 7–50 - NCT07335601RecruitingPhase 2
Resmetirom for liver health after transplant in MASH patients
This trial tests an experimental drug, resmetirom, to see if it can help people who have had a liver transplant for MASH and now have fatty buildup in their new liver. It may also help people who had a transplant for other reasons but developed fatty liver afterward. The study focuses on those with moderate to advanced liver scarring (F2-F3).
La Jolla, CaliforniaAges 18–75 - NCT05424003RecruitingPhase 2
Semaglutide to prevent weight gain after liver transplant
This trial tests semaglutide (a diabetes/weight-loss medicine) to help prevent weight gain after liver transplant. It is also looking at blood sugar and safety while you continue your transplant medicines.
Richmond, VirginiaAges 18–75 - NCT06751602Enrolling by invitationPhase 2
Belumosudil to prevent kidney scarring after transplant
This trial tests whether a drug called belumosudil can reduce scarring in the kidney after transplant. Scarring can lead to kidney damage over time, and this study aims to stop that from happening.
Houston, TexasAges 18–75 - NCT05195944Enrolling by invitationPhase 4
Semaglutide versus sitagliptin after liver transplant for diabetes
This trial compares two diabetes medicines—semaglutide and sitagliptin—in people who have had a liver transplant and have type 2 diabetes (or diabetes after transplant). It’s looking to see which medicine works better and is safe for blood sugar control in the transplant setting.
Toronto, OntarioAges 18 years+ - NCT06557564Recruiting
Liver transplant biopsy study using TruGraf
This study uses a blood test called TruGraf to check for liver transplant problems. It may help diagnose issues without a biopsy.
Toronto, OntarioAges 18 years+ - NCT05525507RecruitingPhase 1
Test early immune-tolerance treatment for matched kidney transplant patients
This Phase 1 study tests a treatment plan given after a kidney transplant to help the immune system stay calm and reduce the risk of rejection. Participants must have a well-functioning kidney transplant from a closely matched living donor and meet health and safety requirements.
Los Angeles, CaliforniaAges 18 years+ - NCT06794970Recruiting
Tissue study for chronic kidney transplant rejection
This study looks at tissue samples from kidney transplant patients who have a specific type of long-term rejection called chronic active humoral rejection (cAMR). It aims to better understand the condition and help future patients.
Bologna, BOAges 18 years+
Hear when a new Liver Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver transplant rejection?
- Yes. Clin2 currently lists 37 recruiting liver transplant rejection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver transplant rejection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver transplant rejection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.